Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Boule Diagnostics AB ( (SE:BOUL) ) is now available.
Boule Diagnostics AB reported a challenging second quarter in 2025, with net sales declining by 5.6% due to unfavorable currency impacts and price pressures. Despite these challenges, the company saw a 16.5% increase in instrument sales, reflecting strong demand for their 5-part technology. The gross margin decreased due to a lower average selling price, but the company achieved a positive operating cash flow, highlighting effective cost management. Leadership changes were made to support strategic growth, including new appointments to strengthen the R&D and sales teams.
More about Boule Diagnostics AB
Boule Diagnostics AB is a company operating in the diagnostics industry, primarily focusing on the development and sale of hematology instruments and consumables. The company is positioned in the market to provide diagnostic solutions, with a strategic emphasis on expanding its installed base to drive future reagent growth.
Average Trading Volume: 60,107
Current Market Cap: SEK385.2M
Find detailed analytics on BOUL stock on TipRanks’ Stock Analysis page.